Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| bryostatin 1, paclitaxel | PRKCA | SSL via PRKCA | 2 | ||||||||
| olaparib | PARP3 | SSL via PARP3 | 2 | ||||||||
| 18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography | PARP3 | SSL via PARP3 | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| azd1775, olaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| bevacizumab, cediranib, cediranib maleate, olaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, pembrolizumab | PARP3 | SSL via PARP3 | 1 | ||||||||
| biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, placebo administration | PARP3 | SSL via PARP3 | 1 | ||||||||
| capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab | PARP3 | SSL via PARP3 | 1 | ||||||||
| ceralasertib, olaparib, durvalumab | PARP3 | SSL via PARP3 | 1 | ||||||||
| cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab | PARP3 | SSL via PARP3 | 1 | ||||||||
| cytoreductive surgery, perifosine, temsirolimus | PRKCA | SSL via PRKCA | 1 | ||||||||
| durvalumab, olaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| durvalumab, olaparib, cediranib | PARP3 | SSL via PARP3 | 1 | ||||||||
| ep0057, olaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| fluorouracil, irinotecan sucrosofate, laboratory biomarker analysis, leucovorin calcium, rucaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery | PRKCA | SSL via PRKCA | 1 | ||||||||
| nab-paclitaxel, gemcitabine, cisplatin, irinotecan, capecitabine, pembrolizumab, olaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| olaparib, olaparib, placebo, placebo | PARP3 | SSL via PARP3 | 1 | ||||||||
| olaparib, ramucirumab | PARP3 | SSL via PARP3 | 1 | ||||||||
| olaparib, temozolomide (tmz), imrt (intensity modulated radiation therapy) | PARP3 | SSL via PARP3 | 1 | ||||||||
| olaparib, temozolomide, gene expression analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, therapeutic conventional surgery | PARP3 | SSL via PARP3 | 1 | ||||||||
| olaparib, temozolomide, irinotecan | PARP3 | SSL via PARP3 | 1 | ||||||||
| paclitaxel, bryostatin 1 | PRKCA | SSL via PRKCA | 1 | ||||||||
| pamiparib, olaparib, radiation therapy, temozolomide | PARP3 | SSL via PARP3 | 1 | ||||||||
| pembrolizumab, olaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| pembrolizumab, olaparib, temozolomide | PARP3 | SSL via PARP3 | 1 | ||||||||
| perifosine | PRKCA | SSL via PRKCA | 1 | ||||||||
| rucaparib | PARP3 | SSL via PARP3 | 1 | ||||||||
| rucaparib, ramucirumab, nivolumab | PARP3 | SSL via PARP3 | 1 | ||||||||
| tamoxifen, etoposide | PRKCA | SSL via PRKCA | 1 | ||||||||
| midostaurin | PRKCA | SSL via PRKCA | yes | 0 |